UCB Pharma

UCB announcement UCB Pharma (Belgium) announced in 1997 its decision to install a SMB made of columns of 45 cm i.d. in order to perform large-scale manufacturing for a promising new class of drugs. UCB decided to replace a classical chemical process used in the pharmaceutical industry by SMB technology. 

Particular examples for the separation of optical isomers in the (pharmaceutical) industry include prazinquatel [51], 3-blockers [52], chiral epoxide [6],thia-diazin EMD5398 [18] and hetrazipine [7]. The Belgian company UCB Pharma uses a large-scale SMB from NOVASEP to perform optical isomer separation at a scale of several tons per year. Almost all of these separations are performed on cellulose-based stationary phases using organic eluents [4]. 

The authors are very grateful to Michel Hamende and Xavier Baert from UCB Pharma and to Velvet Mitchem from Novasep. 

Explain the main differences between the above post-merger integration and the integration of UCB Pharma and Celltech, executed against even more ambitious targets ... 

On the surface, the integration of UCB Pharma and Celltech was very similar to the integration of UCB Chemical and UCB Films with Solutia s resins, additives, and adhesives business. It covered about EUR 2.1 billion in revenue and 8,500 people the aspiration was to achieve the same improvement target (five percent on sales before the merger, increased to around ten percent on sales in the planning phase) and the plan was to realize this through a similar four-phase integration approach (Fig. 26.3). 

Second, on top of the financial ambitions, and even more so than on the chemicals side, the new, externally-recruited Sector Head wanted to leverage the merger to fundamentally transform UCB Pharma. The new UCB Pharma had to ... 

Merge the proven commercial success of UCB Pharma with the innovation and R D capability of Celltech ... 

Thrive upon a set of strong values, which distinguish UCB Pharma from traditional biotech companies as well as from conventional pharmaceutical majors ... 

People feel involved and inspired by what the new UCB Pharma stands for. In a recent survey of the top 170 leaders, 63 percent of people described their engagement in the new entity as outstanding, 33 percent as very good, and four percent as good. Nobody rated it as average or poor ... 

Last but not least, top-line and bottom-line results are exceeding expectations, and the extra profits UCB Pharma is making compensate for the profits lost due to the divestment of Surface Specialties. 

Trade names Aflamin Arrestin Beofenac Preservex (UCB Pharma)... 

Trade names Harkoseride Vimpat (UCB Pharma) Indications Partial-onset seizures Category Antiepileptic Half-life 13 hours... 

Trade names Vozet Xozal Xusal Xyzal (UCB Pharma) Indications Allergic rhinitis, chronic idiopathic urticaria Category Antihistamine Half-life 6-10 Hours... 

Our work on the Na channel genes has been supported by the National Institute of General Medical Sciences (GM24872), the National Institute of Neurological Diseases and Stroke (NS34509), the March of Dimes, and the American Epilepsy Foundation with support from UCB Pharma, Inc. 

This work was supported by research grants NS 31173 and NS 35127 and a research contract from UCB Pharma. Portions of this work have been presented previously in abstract form. Some of the data summarized herein have been published previously. In addition, the synthesis and biological activity of bivalent ligands will be presented in greater detail in a future publication. 

Bruno Boulanger, Ph.D., UCB Pharma SA, Braine-L alleud, Belgium... 

EtOH) poorly soluble in H2O (430 mg/100 ml), soluble in organic solvents LDso (rat orl) = 8.2 g/kg. Allchem Ind BASF Corp. Bayer AG CK Witco Corp. Daihachi Chem. Ind. Co. Ltd Degussa-Huls Corp. Eastman Chem. Co. Ftuka Morflex Inc. UCB Pharma. 

Hyoscine Injection (Hyoscine hydrobromide). UCB Pharma Ltd UK Summary of product characteristics, June 2005. 

---